Evidence map›Paper›PMID 36105050›Full record

ArticleAmerican journal of translational research2022

Dendritic cells modified by tumor associated antigen SMP30 have enhanced antitumor effect against mouse hepatocarcinoma cells in vitro and in vivo.

Jinhong Guo, Yaoyao Zhang, Qiuhong Qin, Naixia Chao, Tianming Huang, Chengxiao Chen, Xiaoling Lu, Rongshi Huang, Jian Pan

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jinhong GuoCollege of Stomatology, Hospital of Stomatology/Guangxi Key Laboratory of Nanobody Research/Guangxi Nanobody Engineering Research Center, Guangxi Medical University Nanning 530021, Guangxi, P. R. China.
Yaoyao ZhangDepartment of Histology and Embryology, Guangxi Medical University Nanning 530021, Guangxi, P. R. China.
Qiuhong QinDepartment of Pathology, Jiangbin Hospital of Guangxi Zhuang Autonomous Region Nanning 530021, Guangxi, P. R. China.
Naixia ChaoDepartment of Histology and Embryology, Guangxi Medical University Nanning 530021, Guangxi, P. R. China.
Tianming HuangDepartment of Histology and Embryology, Guangxi Medical University Nanning 530021, Guangxi, P. R. China.
Chengxiao ChenDepartment of Histology and Embryology, Guangxi Medical University Nanning 530021, Guangxi, P. R. China.
Xiaoling LuCollege of Stomatology, Hospital of Stomatology/Guangxi Key Laboratory of Nanobody Research/Guangxi Nanobody Engineering Research Center, Guangxi Medical University Nanning 530021, Guangxi, P. R. China.
Rongshi HuangDepartment of Histology and Embryology, Institute of Preclinical, Guangxi Traditional Chinese Medical University Nanning 530001, Guangxi, P. R. China.
Jian PanDepartment of Human Anatomy, Guangxi Medical University Nanning 530021, Guangxi, P. R. China.
Guangxi Medical University · CNGuangxi University of Chinese Medicine · CNRiverside Hospital of Guangxi Zhuang Autonomous Region · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTumor immunotherapy based on dendritic cells (DC) is one of the most promising approaches to treat cancers. This therapy uses an immunogenic tumor antigen to present it to T cells. Senescence marker protein 30 (SMP30) is identified as a tumor associated antigen (TAA) with high immunogenicity and specificity for hepatocellular carcinoma (HCC). DCs are the most potent antigen presenting cells, and can be transduced with tumor antigens to enhance antitumor immune response. The purpose of this study was to investigate the antitumor effect of DCs transduced with a recombinant lentiviral vector (

methodsA recombinant lentiviral vector (

resultsThe

conclusionDCs transduced with

Indexed as

Dendritic cellimmunotherapylentivirus vectorsenescence marker protein 30

Identifiers

PMID36105050
PMCPMC9452339
OpenAlexW4295905729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.